Literature DB >> 16304371

The molecular pathology of acute myeloid leukemia.

Jonathan D Licht1, David W Sternberg.   

Abstract

The pathogenesis of acute myelogenous leukemia (AML) involves an array of molecular alterations that disrupt almost every facet of cell transformation. These processes include the regulation of cell proliferation, differentiation, self-renewal, survival, cell cycle checkpoint control, DNA repair and chromatin stability, and cell dissemination. Normal regulatory networks are disrupted or usurped by these leukemogenic insults, and the understanding of these alterations is guiding the design of new therapeutic strategies. This overview describes some of the critical molecular alterations and implicates the rogue leukemogenic proteins in the onset and progression of AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304371     DOI: 10.1182/asheducation-2005.1.137

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  14 in total

1.  Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.

Authors:  Timothy S Pardee; Evan Gomes; Jamie Jennings-Gee; David Caudell; William H Gmeiner
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

Review 2.  Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Christopher R Cogle; Bart L Scott; Thomas Boyd; Guillermo Garcia-Manero
Journal:  Oncologist       Date:  2015-10-13

Review 3.  Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Authors:  Shaheedul A Sami; Noureldien H E Darwish; Amanda N M Barile; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2020-01-13

4.  HOX deregulation in acute myeloid leukemia.

Authors:  Kim L Rice; Jonathan D Licht
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

Review 5.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

6.  Granulocyte colony stimulating factor increases drug resistance of leukaemic blast cells to daunorubicin.

Authors:  László Márkász; György Hajas; Andrea Kiss; Beáta Lontay; Eva Rajnavölgyi; Ferenc Erdodi; Eva Oláh
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

Review 7.  Animal models of leukemia: any closer to the real thing?

Authors:  Guerry J Cook; Timothy S Pardee
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

8.  Efficacy of 10-day decitabine in acute myeloid leukemia.

Authors:  Ian M Bouligny; Vivek Mehta; Scott Isom; Leslie R Ellis; Rupali R Bhave; Dianna S Howard; Susan Lyerly; Megan Manuel; Sarah Dralle; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2021-02-12       Impact factor: 3.156

9.  Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc.

Authors:  Qiang Liu; Na Liu; Shaolei Zang; Heng Liu; Pin Wang; Chunyan Ji; Xiulian Sun
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

10.  Acute myeloid leukemia with KMT2A-SEPT5 translocation: A case report and review of the literature.

Authors:  Shaimaa Elzamly; Santosh Chavali; Vijay Tonk; Sahil Tonk; Sumit Gaur; Darlene Tarango; Alireza Torabi
Journal:  SAGE Open Med Case Rep       Date:  2018-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.